EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Application of teriparatide in CKD-related osteoporosis: efficacy and safety considerations

Lin Luo

International Urology and Nephrology · 2025

DOI: 10.1007/s11255-025-04599-8 ↗

Kurz gefasst

Leserbrief in der Zeitschrift International Urology and Nephrology, 2025. Verfasst von Lin Luo. Beteiligte Einrichtung: Department of Orthopedics, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, NO.182, Chunhui Road, Longmatan Distri…. Hauptthemen laut MEDLINE: Bone Density Conservation Agents, Osteoporosis, Renal Insufficiency, Chronic, Teriparatide. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben. Gefördert von: Luzhou Science and Technology Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The efficacy and safety of teriparatide in treating osteoporosis associated with chronic kidney disease (CKD) exhibit variability. Vetrano et al. demonstrated that teriparatide can improve bone density in renal transplant recipients with low bone turnover, with a favorable safety profile. In contrast, Hara et al. found that alendronate was more effective in preventing fractures in patients with CKD stages 3b/4. This discrepancy may be linked to CKD staging and the degree of bone metabolic disturbances. Responses in bone turnover markers are also inconsistent. In advanced CKD patients, the increase in bone resorption markers is limited. The risk of hypercalcemia (22.2%) is associated with the patient's calcium-phosphate metabolism status and parathyroid function. Future research should incorporate bone biopsy and multicenter studies to clarify the efficacy differences across CKD stages and bone turnover types, optimizing individualized application strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone Density Conservation AgentsOsteoporosisRenal Insufficiency, ChronicTeriparatideHumansBone DensityTreatment Outcome

Substanzen

Bone Density Conservation AgentsTeriparatide

Autor:innen und Institutionen

  • Department of Orthopedics, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, NO.182, Chunhui Road, Longmatan District, Luzhou, 646000, Sichuan Province, People's Republic of China. luol…

Förderung

  • Luzhou Science and Technology Program

Zitieren

APA

Luo, L. (2025). Application of teriparatide in CKD-related osteoporosis: efficacy and safety considerations. International Urology and Nephrology. https://doi.org/10.1007/s11255-025-04599-8

Vancouver

Luo L. Application of teriparatide in CKD-related osteoporosis: efficacy and safety considerations. International Urology and Nephrology. 2025. doi:10.1007/s11255-025-04599-8

BibTeX
@article{Luo2025,
  author = {Luo, Lin},
  title = {Application of teriparatide in CKD-related osteoporosis: efficacy and safety considerations},
  journal = {International Urology and Nephrology},
  year = {2025},
  doi = {10.1007/s11255-025-04599-8}
}
Kostenlos starten →